

# ASX Announcement



Medibio Limited – 8 October 2018

## **Medibio Technology Honored with Two Presentations at Mayo Clinic Convergence Neuroscience 2018**

**Sydney, Australia and Minneapolis, MN USA – 8 October 2018: Medibio Limited (MEB or the Company)**(ASX: MEB)(OTCQB: MDBIF), a mental health technology company, is happy to announce that two clinical abstracts by Dr. Archie Defillo et al. have been accepted for presentation as part of the Mayo Clinic Convergence Neuroscience 2018 Course. Both presentations are based on the recently completed DX04 clinical study.

Dr. Archie Defillo, Chief Medical Officer at Medibio, will share the following abstract presentations during the event to be held on November 8-10, 2018:

1. A Machine Learning Based Approach to Identify Heart Rate Variability Patterns Serving as a Diagnostic Aid for Major Depressive Episodes.
2. A Novel Technology in Mental Health Variations in Cardio-Autonomic Function Used as Diagnostic Support for Major Depressive Episodes.

Physicians and nurses attending the conference receive continuing medical education credit from the American Medical Association and the American Nurses Credentialing Center. The conference calls for groups within the biomedical, life sciences, physical science, engineering, and other fields to come together to solve unmet health needs. The goal is to bring together various scientists with the aim of discovery of education gaps and the potential for creative collaboration in shared problem solving.

“We are extremely proud of our clinical team and Scientific Advisory Board for their efforts in the significant research accepted for presentation at Mayo Clinic Convergence Neuroscience 2018,” says Brian Mower, Interim Chief Executive Officer at Medibio. “This honor further validates our scientific research, as we continue our work solving unmet health needs with objective solutions to mental health.”

- ENDS -

# ASX Announcement



Medibio Limited – 8 October 2018

## **About Medibio Limited**

Medibio (ASX: MEB) (OTCQB: MDBIF) is a mental health technology company that has pioneered the use of objective digital biomarkers to assist in the screening, diagnosing, monitoring and management of depression and other mental health conditions. The company was founded in Australia, with offices located in Melbourne (Vic), Perth (Wa) and U.S. offices in Minneapolis, MN. Medibio is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on [www.otcmarkets.com](http://www.otcmarkets.com) and [www.asx.com.au](http://www.asx.com.au).

## **Further Information:**

### **Medibio Enquiries:**

Josh Purdy  
Senior Public Relations Manager  
Medibio Limited  
[josh.purdy@medibio.com.au](mailto:josh.purdy@medibio.com.au)  
T: +1 952 314 1216

Website: [www.medibio.com.au](http://www.medibio.com.au)

### **Australian Media Enquiries:**

Peter Taylor  
NWR Communications  
[peter@nwrcommunications.com.au](mailto:peter@nwrcommunications.com.au)  
T: +61 (0) 412 036 231